Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OpRegen
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal, Intraocular
01
Overview
OpRegen (RG6501) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in Phase 2a clinical development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The therapy consists of human embryonic stem cell-derived RPE cells that are delivered via subretinal injection to replace or support the damaged RPE layer in patients with GA. By restoring the RPE layer, OpRegen aims to preserve the overlying photoreceptors and prevent further vision loss. The program was originally developed by Lineage Cell Therapeutics and its subsidiary Cell Cure Neurosciences, and is now being advanced through a worldwide collaboration with Roche and Genentech. It has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
- Brand names
- OpRegen
- Other names
- human embryonic stem cell-derived retinal pigment epithelial cellsRPE cell therapyallogeneic RPE cell therapy
Beyond the preview
Go deeper on OpRegen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OpRegen.